REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al. ; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
3. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528-62.
4. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
5. Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:708-22.
6. Marjot T, Armstrong MJ, Stine JG. Skeletal muscle and MASLD: mechanistic and clinical insights. Hepatol Commun. 2025;9:e0711.
7. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15:321-35.
8. Yuan S, Larsson SC. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism. 2023;144:155533.
10. Chen LK, Hsiao FY, Akishita M, et al. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nat Aging. 2025;5:2164-75.
11. Kirk B, Cawthon PM, Arai H, et al. ; Global Leadership Initiative in Sarcopenia (GLIS) group. The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing. 2024;53:afae052.
12. Xia L, Zhao R, Wan Q, et al. Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med. 2020;9:7964-78.
13. Harring M, Golabi P, Paik JM, et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin Gastroenterol Hepatol. 2023;21:2876-88.e5.
14. Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S68-78.
15. Kuchay MS, Martínez-Montoro JI, Kaur P, Fernández-García JC, Ramos-Molina B. Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk. Ageing Res Rev. 2022;80:101696.
16. Basil B, Adiri W, Ugwu EL, Okoro NI. Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025;17:457.
17. Aggeletopoulou I, Tsounis EP, Triantos C. Vitamin D and metabolic dysfunction-associated steatotic liver disease (MASLD): novel mechanistic insights. Int J Mol Sci. 2024;25:4901.
18. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-61.
19. Lou TW, Yang RX, Fan JG. The global burden of fatty liver disease: the major impact of China. Hepatobiliary Surg Nutr. 2024;13:119-23.
20. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-50.
21. Nishikawa H, Kim SK, Yoshio S, Asai A. Metabolic dysfunction-associated steatotic liver disease and sarcopenia: review of literature. J Clin Med. 2026;15:1661.
22. Linge J, Ekstedt M, Dahlqvist Leinhard O. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Rep. 2021;3:100197.
23. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. ; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31.
24. Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024;43:2005-16.
25. Malik A, Javaid S, Malik MI, Qureshi S. Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Ann Hepatol. 2024;29:101544.
26. Xia N, Wang J, Lu Q, Fan X, Jiang Z, Yu Q. Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: a systematic review and meta-analyses. Clin Nutr ESPEN. 2025;68:679-90.
27. Giustina A, Bilezikian JP, Adler RA, et al. Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr Rev. 2024;45:625-54.
28. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109:1907-47.
29. Man PW, van der Meer IM, Lips P, Middelkoop BJ. Vitamin D status and bone mineral density in the Chinese population: a review. Arch Osteoporos. 2016;11:14.
30. Yodoshi T, Orkin S, Arce-Clachar AC, et al. Vitamin D deficiency: prevalence and association with liver disease severity in pediatric nonalcoholic fatty liver disease. Eur J Clin Nutr. 2020;74:427-35.
31. Heo NJ, Park HE, Yoon JW, et al. The association between vitamin D and nonalcoholic fatty liver disease assessed by controlled attenuation parameter. J Clin Med. 2021;10:2611.
32. Ebrahimpour-Koujan S, Sohrabpour AA, Giovannucci E, Vatannejad A, Esmaillzadeh A. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutr J. 2024;23:24.
33. Khanmohammadi S, Kuchay MS. Effects of metabolic dysfunction-associated steatotic liver disease on bone density and fragility fractures: associations and mechanisms. J Obes Metab Syndr. 2024;33:108-20.
34. Goldscheitter GM, Seneshaw M, Mirshahi F, et al. Sexual dimorphism of MASLD-driven bone loss. Sci Rep. 2025;15:23090.
35. Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36:947-68.
36. Carli F, Della Pepa G, Sabatini S, Vidal Puig A, Gastaldelli A. Lipid metabolism in MASLD and MASH: from mechanism to the clinic. JHEP Rep. 2024;6:101185.
37. Liu CH, Zeng QM, Kim W, et al. Sarcopenia and MASLD: novel insights and the future. Nat Rev Endocrinol. 2026;22:139-52.
38. Wang P, Liu X, Du X, et al. Prevalence and risk of metabolic dysfunction-associated steatotic liver disease in patients with sarcopenic obesity: a systematic review and meta-analysis. Nutr Metab. 2025;22:101.
39. Milani I, Codini M, Guarisco G, et al. Hepatokines and MASLD: the GLP1-Ras-FGF21-Fetuin-A crosstalk as a therapeutic target. Int J Mol Sci. 2024;25:10795.
40. Pezzino S, Puleo S, Luca T, Castorina M, Castorina S. Adipokine and hepatokines in metabolic dysfunction-associated steatotic liver disease (MASLD): current and developing trends. Biomedicines. 2025;13:1854.
41. Nishikawa H, Kim SK, Asai A. The role of myokines in liver diseases. Int J Mol Sci. 2025;26:1043.
42. Aguirre F, Valero-Breton M, Cabrera D, et al. Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review. Eur J Transl Myol. 2025;35:13365.
43. Wang JL, Xiao Y, Li ML, Chen GL, Cui MH, Liu JL. Research progress on leptin in metabolic dysfunction-associated fatty liver disease. J Clin Transl Hepatol. 2025;13:964-75.
44. Liu J, Song Y, Wang Y, Hong H. Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease. Expert Opin Ther Targets. 2023;27:1145-57.
45. Gupta V, Krishnamoorthy A. Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: a critical review of diagnostic, mechanistic, and therapeutic intersections. World J Gastroenterol. 2025;31:110481.
46. Kerminen H, Jyväkorpi S, Urtamo A, et al. Performance of the SARC-F, SARC-CalF, and calf circumference for sarcopenia case finding in community-dwelling older adults. Eur Geriatr Med. 2024;15:1817-26.
47. Ju C, Yao L, Yoon SY, et al. Defining reference values for skeletal muscle metrics on abdominal CT using data from healthy young adult populations: a systematic review and meta-analysis. AJR Am J Roentgenol. 2025;225:e2532781.
48. Yang J, Liu Q, Sun C. Quality and quantity? The clinical significance of myosteatosis in various liver diseases: a narrative review. J Clin Transl Hepatol. 2025;13:1092-106.
49. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172-93.
50. Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38:485-521.
51. Fan JG, Xu XY, Yang RX, et al. ; Chinese Society of Hepatology, Chinese Medical Association. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024). J Clin Transl Hepatol. 2024;12:955-74.
52. Medeiros DG, Ferreira LF, Lamp JDS, Telles da Rosa LH. The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review. Eur J Gastroenterol Hepatol. 2025;37:129-36.
53. Lin YY, Qian D, Lin L, Chen S, Jing XC. Advanced exercise intervention for liver cirrhosis and sarcopenia: a development and feasibility study. Medicine. 2025;104:e43974.
54. Hsu HC, Chow LH, Chen YL, Hung HM, Yen M, Lee HF. Effects of exercise and nutrition in improving sarcopenia in liver cirrhosis patients: a systematic review and meta-analysis. Hepatobiliary Surg Nutr. 2025;14:33-48.
55. Brown A, Dias I, da Silva Novaes J, et al. A resistance training program on patients with liver cirrhosis: a randomized clinical trial. Int J Environ Res Public Health. 2025;22:1257.
56. Yang S, Chen S, Zhang Y, Zhou Z, Li D, Zeng P. Effects of Tai Chi and Baduanjin on muscle mass, muscle function, and activities of daily living in individuals with sarcopenia: a systematic review and meta-analysis. Front Public Health. 2025;13:1636857.
57. Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation 2024;150:1288-98.
58. Martinekova P, Obeidat M, Topala M, et al. Role of vitamin D supplementation in chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2025;83:2043-54.
59. Taheri E, Esmaeili S, Jodeiri F, et al. Vitamin D supplementation for steatotic liver disease: an updated systematic review and dose-response meta-analysis of randomized and nonrandomized interventional studies. Curr Dev Nutr. 2026;10:107631.
60. Harrison SA, Bedossa P, Guy CD, et al. ; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
61. Sanyal AJ, Newsome PN, Kliers I, et al. ; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
62. Moscucci F, Baratta F, Pastori D, et al. A narrative review on GLP-1 receptor agonists for obesity in older women: maximizing weight loss while preserving lean mass. Nutrients. 2026;18:632.
